The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 21, Taili Biotech Co., Ltd. (Taili Biotech for short) submitted a listing application to the main board of the Hong Kong Stock Exchange, and CITIC Securities is its sole sponsor. The company submitted a listing application to the Hong Kong Stock Exchange on January 29. According to the prospectus, Taili Biotech is a clinical-stage biopharmaceutical company founded in 2017, focusing on the discovery and development of oncology therapies. As of the last practical date, Taili Biotech's drug portfolio includes four drug candidates, including a core product TSN1611 in phase 2 clinical trials, another clinical-stage candidate TSN222, and two pre-clinical drug candidates TSNA1789 and TSNA3339. The company's core product, TSN1611, is an oral Kirsten rat sarcoma virus cancer congener (“KRAS”) G12D inhibitor.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.